Title of Research Paper |
Particip. |
Stage IIA |
Followup |
|
Under each title, I have
included blurbs or quotes from the actual abstract or full paper (when
available). |
||||
| Treatment
results in women with clinical stage I and pathological stage II endometrial
carcinoma J. J. Jobsen, E. M. J. Schutter, J. H. Meerwaldt, J. Van Der Palen, R. Van Der Sijde & L. Naudin Ten Cate Int J Gynecol Cancer 2001;11:49–53. |
||||
| The aim of this study is to report survival and results of therapy and possible prognostic factors in women with pathologic stage II endometrial carcinoma....All patients received external radiotherapy following standard surgical procedures and no adjuvant systemic therapy was given....There was a significant different 5-year disease specific survival for stage IIA and IIB, respectively, 95% and 74% | 42 |
21 |
62 mo. |
|
| Stage
I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the
role of surgery and adjuvant radiation K. Look Int J Gynecol Cancer 2002;12:237–249. |
||||
| Review of Medline articles from 1975 to 2001...The papers were assessed with regard to (a) extent of surgical staging (b) type of adjuvant radiotherapy utilized: external vs. brachytherapy vs. combination therapy; and (c) whether the patients were treated as part of prospective trial or reported as a descriptive series reflecting an institution's practice pattern....Survival rates are excellent for patients with early stage disease treated in either paradigm of extended-surgical staging with more restricted use of the adjuvant therapy or simple hysterectomy bilateral salpingoophorectomy with more frequent use of adjvuant radiotherapy. | ||||
Clinical
behavior of 203 stage II endometrial cancer cases: The impact of primary
surgical approach and of adjuvant radiation therapy E. Sartori*, A. Gadducci, F. Landoni, A. Lissoni, T. Maggino, P. Zola& V. Zanagnolo |
||||
| The aim of this study was to verify the impact of primary surgical approach and adjuvant radiation therapy (RT) on survival, recurrence rate, and pattern of relapse in stage II endometrial cancer patients...Actuarial survival rates for stage IIA and IIB were 86% and 74% at 5 years and 82% and 68% at 10 years, respectively....Most of the relapses were locoregional in the observation group and distant in the RT group. Survival rates by RT were not statistically different. Subjects treated with RH improved their survival compared with the SH group; the difference was significant, but randomized studies should confirm this trend. Although adjuvant RT seemed to reduce the recurrence rate, there was no significant difference in survival, and so the role of RT still needs further verification. | 203 |
111 |
10 yrs |
|
| Clinicopathological
study of the pattern and significance of cervical involvement in cases of
endometrial adenocarcinoma L. B. Jordan & A. Al-Nafussi Int J Gynecol Cancer 2002;12:42–48. |
||||
| The pattern of cervical involvement in 107 endometrial adenocarcinomas was assessed. The cervix was involved in 29%, higher than noted in previous studies. In 40.6%, the lesion was confined to surface endocervical epithelium only; the remainder had cervical stromal involvement. In the majority only small areas within the circumference of the cervix were affected, indicating a need for adequate tissue sampling. In some cases, malignant epithelium was found as a "migrant" within the endocervical canal, entrapped within cervical mucus or applied to surface epithelium, supporting the concept that endometrial cancer spreads by surface contiguity or implantation rather than by deep tissue planes or via lymphatic channels.... | 107 |
--- |
--- |
|
Factors
influencing survival in endometrial cancer relapsing patients: a Cooperation
Task Force (CTF) study E. Sartori, B. Laface, A. Gadducci, T. Maggino, P. Zola, F. Landoni & V. Zanagnolo International Journal of Gynecological Cancer 13 (4), 458-465. |
||||
| The purpose of this study was to identify patterns of relapse and to determine the outcome of salvage treatment and the factors influencing survival of endometrial cancer relapsing patients...Of these, 209 (13%) subjects had recurred... Five and 10-year survival rates of patients with recurrent disease was 26% and 22%, respectively. Relapse of endometrial cancer is often early and at distant sites. Survival rate was related to site of relapse, disease-free interval, and postoperative treatment as independent prognostic variables. The site of relapse is the most important predictor of survival of patients with recurrent disease. | 1606 |
--- |
5-10 yrs |
|
| Radical Radiation Therapy Regimen Produces Cure in More than Half of Women with Local Recurrence of Endometrial Cancer | ||||
| Researchers in Toronto treated 58 women with endometrial cancer that recurred in the area of the uterus, none of whom had received prior radiation therapy. The average time from their initial surgery to the cancer recurrence was more than 1 year. All the women underwent radical radiation therapy, which consisted of a combination of external-beam radiation therapy to the uterus area and brachytherapy in most. After 5 years, 53% of the patients were alive; after 10 years, 41% were alive. Overall, survival was better in women who had early-stage disease at diagnosis, smaller cancers at recurrence, and/or lower grade (well differentiated cells under a microscope) disease. | ||||
| A
Higher "Grade" of Cancer of the Endometrium May Indicate Need
for More Aggressive Therapy After Surgery SOURCE: CancerConsultants Oncology Resource Center |
||||
| Researchers in Switzerland have now defined the risk for a cancer recurrence (return), based on the grade of cancer (or degree of differentiation from healthy cells), for women who have undergone surgery and radiation therapy for stage I endometrial cancer. A higher grade of cancer appears to be associated with a greater risk for a cancer recurrence and death, indicating the possible need for chemotherapy or other form of therapy after surgery in these cases....Recurrences of cancer in the uterus area occurred in 4.6% of persons with grade 1 cancers, 9% of those with grade 2 cancers, and 4.6% of those with grade 3 cancers. Recurrences of cancer in other parts of the body (called metastatic cancer) occurred in 1.4% of persons with grade 1 cancers, 6.3% of persons with grade 2 cancers, and 7.2% of persons with grade 3 cancers. Persons who died included 1.4% of those with grade 1 cancers, 6.3% of those with grade 2 cancers, and 20.7% of those with grade 3 cancers. After 5 years, women who were alive and free of disease included 88% who had grade 1 cancers, 77% who had grade 2 cancers, and 67% who had grade 3 cancers....These researchers concluded that grade 1 cancers were associated with the least risk for recurrence and death; grade 2 cancers with the highest risk for metastasis; and grade 3 cancers with the highest risk for death. | ||||
Other interesting research |
||||
Under each title, I have
included blurbs or quotes from the actual abstract or full paper (when
available). |
||||
| Soy-Derived
Estrogens Do Not Stimulate Breast Or Uterine Proliferation NEW YORK JUL 09, 2004 (Reuters Health) Journal of Clinical Endocrinology and Metabolism (2004;89:3462-3468.) |
||||
| ...Dr. Charles E. Wood and colleagues from Wake Forest University Health Sciences, Winston-Salem, North Carolina evaluated markers of breast and uterine proliferation in response to long-term treatment with soy isoflavones or conjugated equine estrogens in a postmenopausal cynomolgus monkey model...Three years of soy isoflavone treatment did not significantly alter epithelial area or sex steroid receptor expression in the breast or uterus, the authors report. In contrast, conjugated equine estrogen treatment brought significant increases in mammary gland and endometrial epithelial area and in progesterone receptor expression...Soy isoflavone treatment brought significantly lower serum estrone and estradiol levels, the results indicate, and total plasma isoflavone levels correlated inversely with serum estrone concentrations and with mammary glandular area... | ||||
| Regular
Soy Intake May Protect Against Endometrial Cancer NEW YORK MAY 27, 2004 (Reuters Health) British Medical Journal 2004;328:1285-1288. |
||||
| Endogenous estrogens are known to play a key role in the pathogenesis of endometrial cancer, investigators report in the May 29th issue of the British Medical Journal. Given that soy foods contain isoflavones with both estrogenic and anti-estrogenic activities, the effect high intake of such foods have on the endometrial cancer risk has been unclear....Intake of soy foods was inversely related to the risk of endometrial cancer, the investigators note. Compared with women who consumed no more than 5.9 g/day of soy protein, those who consumed 6.0 to 10.2, 10.3 to 16.0, or more than 16 g/day were 7%, 15%, and 33% less likely to develop cancer, respectively (p for trend = 0.01).... | ||||
| Soy
Use Linked To Thickening Of Uterus Lining NEW YORK JUL 13, 2004(Reuters Health) Fertility and Sterility, July 2004. |
||||
| Soy contains chemicals called phytoestrogens that can stimulate the growth of cells with estrogen receptors, lead author Dr. Vittorio Unfer and colleagues, from the University of Perugia, note in the medical journal Fertility and Sterility. Although the uterus is known to contain such cells, the effect of long-term soy use on the uterus lining has been unclear....To investigate, the researchers analyzed uterus biopsy specimens taken from 376 postmenopausal women who were randomly selected to receive soy or inactive "placebo" tablets for 5 years. Biopsy specimens were obtained at the beginning of the study, after 30 months, and at the end of study period. A total of 298 women completed the full trial...None of the biopsy specimens showed evidence of cancer. However, nearly 4 percent of women in the soy group developed endometrial hyperplasia compared with none of the women in the placebo group. | ||||
| Regular
Phytoestrogen Consumption Reduces Endometrial Cancer Risk NEW YORK Aug 14, 2003 (Reuters Health) Journal of the National Cancer Institute 2003;95:1158-1164. |
||||
| Estrogen exposure without cyclic exposure to progesterone contributes to the development of endometrial cancer, the authors explain, and phytoestrogens have been shown to lower endogenous estrogen levels....The study included 500 women diagnosed with endometrial cancer between age 35 and 79, matched to a similar number of randomly identified controls. The top quartiles of consumption of total isoflavones and of total lignans were associated with a 41% and 32% reduced risk, respectively, of endometrial cancer, compared with the lowest quartiles of consumption, the authors report...Specifically, the reduced risk of endometrial cancer was associated with higher levels of consumption of the two major isoflavones -- genistein and daidzein -- and of the lignan secoisolariciresinol, the report indicates...."Based on these findings and other literature on phytoestrogens, I believe that recommending a balanced diet that includes reasonable amounts of phytoestrogen-rich foods is an appropriate public health message at this time," Dr. Horn-Ross told Reuters Health. "In my opinion, however, we don't have enough information on phytoestrogen supplements in pill form to make any recommendations in either direction regarding these supplements." | ||||
| More
Evidence That Aspirin Helps Prevent [endometrial] Cancer Derived from material from the Ascribe Medical News Service, 3-14-2001 See also: Aspirin Use Linked to Reduced Ovarian Cancer Risk (3-7-2001) |
||||
| Earlier this month, researchers at the New York University School Of Medicine reported that aspirin taken daily over an extended period of time could cut the risk of ovarian cancer. Now, scientists at the University of South Florida say aspirin may reduce the risk of developing endometrial cancer too...In the March issue of the Journal of Obstetrics and Gynecology, Jeanne L. Becker, PhD. and colleagues report on tests they performed on human endometrial cancer cells in the lab..."The aspirin helps the cells kill themselves, letting the natural process of apoptosis occur. With cell death in check, the malignancy may not have an opportunity to develop," Dr. Becker is quoted as saying... | ||||
| Overexpression
of GLUT1 Detected in Endometrial Adenocarcinoma WESTPORT, Jun 16 (Reuters Health) The journal Cancer, June 15, 2000; 88:2774-2781 |
||||
| The glucose transporter GLUT1 is consistently overexpressed in endometrial adenocarcinomas and atypical hyperplasia, but not in typical hyperplasia, according to study findings in the June 15, 2000 issue of Cancer...When stained with GLUT1 antiserum, all 41 samples of endometrial adenocarcinoma tested positive, the researchers report. In addition, staining was positive in all cases of atypical hyperplasia. In contrast, none of the benign samples had positive staining, according to the report...Moreover, they note, the findings "raise the possibility that some or all foci diagnosed as atypical hyperplasia in fact may be endometrial adenocarcinoma in situ." ...In an interview with Reuters Health, Dr. Burstein stressed that the findings are preliminary, but he hoped that they would be confirmed by other researchers. | ||||
| Estrogen
Replacement Therapy Lowers Recurrence of Endometrial Cancer SOURCE: Reuters Health, Feb. 15, 2000. |
||||
| Estrogen replacement therapy apparently improves disease-free survival in women with a history of endometrial cancer, according to results presented this month (Feb. 2000) at the annual meeting of the American Society of Gynecologic Oncologists....Dr. DiSaia and colleagues matched 75 women who had survived stage I to III endometrial cancer and had received hormone replacement therapy, with an equivalent number of controls that did not take estrogen....During follow-up over a median interval of 83 months, two of the patients taking estrogen had local disease recurrence. After a median follow-up of 69 months, 11 women not taking estrogen had cancer recur either locally or at distant sites....Also, overall disease-free survival was 82% for women taking estrogen, compared with 64% of women not taking estrogen, which was also statistically significant...."The established long-term health benefits of estrogen replacement as they impact on the quality of life seem to outweigh the as yet unfounded theoretical risk of disease recurrence," Dr. DiSaia's group writes. However, they suggest that patients should also be counseled on available nonhormonal treatments, which may still provide some of the benefits of estrogen replacement therapy. | ||||
Sonography
May Help Predict Recurrences in Asymptomatic Women with Gynecologic Cancers |
||||
| According to a recent article published in Gynecologic Oncology, the use of ultrasound, or sonography, appears highly accurate in detecting cancer recurrences in women diagnosed with gynecologic cancers who display no other symptoms of a recurrence...Follow-up examinations included a clinical examination, blood tests, CT/MRI scans, and vaginal and abdominal sonography....1) Ultrasound detected areas of concern in 21.5% of women. 2) Among women who displayed no symptoms of a recurrence, sonography accurately detected nearly 100% of recurrences. 3) Among women who displayed symptoms of a recurrence or had signs of a recurrence from a blood test, sonography was not as accurate. 4) 37% of women with a single site of a recurrence had it centrally located within the pelvis. | ||||
Research on mediation, yoga, diet,
and other complimentary activities |
||||
Under each title, I have
included blurbs or quotes from the actual abstract or full paper (when
available). |
||||
| Composite
effects of group drumming music therapy on modulation of neuroendocrine-immune
parameters in normal subjects. Meadville Medical Center's Mind-Body Wellness Center, 18201 Conneaut Lake Rd, Meadville, PA 16335, USA. PMID: 11191041 [PubMed - indexed for MEDLINE] |
||||
| A total of 111 age- and sex-matched volunteer subjects (55 men and 56 women, with a mean age of 30.4 years) were recruited....Group drumming resulted in increased dehydroepiandrosterone-to-cortisol ratios, increased natural killer cell activity, and increased lymphokine-activated killer cell activity without alteration in plasma interleukin 2 or interferon-gamma, or in the Beck Anxiety Inventory and the Beck Depression Inventory II. CONCLUSIONS: Drumming is a complex composite intervention with the potential to modulate specific neuroendocrine and neuroimmune parameters in a direction opposite to that expected with the classic stress response. | ||||
| Top
Cancer-Fighting Foods: Mounting evidence shows that the foods we eat weigh
heavily in the war against cancer. SOURCE: WebMD article by Elizabeth Heubeck, MA |
||||
"The easiest, least-expensive way to reduce your risk for cancer is just by eating a healthy diet," says Rachael Stolzenberg-Solomon, PhD, MPH, RD, a researcher at the National Cancer Institute...Folate rich foods, Vitamin D, Tea, Cruciferous Veggies, Cumin (curry powder), Ginger. See also: Tea May Fight Ovarian, Breast Cancers, Crunchy Veggies Fight Cancer, Vitamin D May Protect Against Cancer |
||||